Clinical Trial Results:
A Randomized, Double-Blind Phase 1/2 Study of INCB039110 in Combination With Erlotinib Versus Erlotinib Alone in Subjects With Stage IIIB, Stage IV, or Recurrent Non–Small Cell Lung Cancer Whose Tumors Have Epidermal Growth Factor Receptor–Activating Mutations
Summary
|
|
EudraCT number |
2015-001642-28 |
Trial protocol |
GB |
Global completion date |
|
Paediatric regulatory details
|
|
Is the trial part of an agreed EMA paediatric investigation plan? |
|
Is the trial in scope of article 45 of Regulation (EC) No 1901/2006? |
|
Is the trial in scope of article 46 of Regulation (EC) No 1901/2006? |
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
07 May 2021
|
First version publication date |
07 May 2021
|
Other versions |
|
Summary report(s) |
Study Withdrawal |
Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to Commission Guideline 2012/C 302/03
for further information.